☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
atara biotherapeutics
Atara Biotherapeutics Reports the US FDA’s BLA Acceptance with Priority Review of Tabelecleucel to Treat Post-Transplant Lymphopro...
July 18, 2024
PharmaShots Weekly Snapshots (May 27 – May 31, 2024)
May 31, 2024
Atara Biotherapeutics Reports Preclinical Data on ATA3219 to Treat B-Cell Driven Autoimmune Diseases
May 30, 2024
Atara Biotherapeutics Reports Results for ATA188 in P-II Trial for the Treatment of Non-Active Progressive Multiple Sclerosis
November 9, 2023
Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Glob...
November 6, 2023
Atara Biotherapeutics Ebvallo (tabelecleucel) Receives EC’s Approval for Epstein‑Barr Virus Positive Post‑Transplant Lymphoprolife...
December 20, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.